JPRN-UMIN000040611Completed未知
ong-term effects of ipragliflozin on nonalcoholic fatty liver disease in patients with type 2 diabetes - Long-term effects of ipragliflozin on NAFLD in patients with type 2 diabetes
Ogawa Red Cross Hospital0 sites66 target enrollmentStarted: June 1, 2020Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 66
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to 75years-old (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Patients who have history or current serious diabetic complication. 2. Patients that insulin dependence is suspected. 3. Patients who have history or current cardiac failure (New York Heart Association Class III or IV), myocardial infarction or cerebrovascular disorder. 4. Patients whose eGFR lower than 45 mL/min/1.73m2, serum creatinine higher than 1.5 mg/dL.
Investigators
Similar Trials
Completed
Not Applicable
Effects of ipragliflozin on nonalcoholic fatty liver disease in patients with type 2 diabetesType 2 diabetes with nonalcoholic fatty liver diseaseJPRN-UMIN000022651Ogawa Red Cross Hospital60
Completed
Phase 2
effect of Empagliflozine on the Non-Alchoholic Fatti Liver DiseaseIRCT20210811052150N1Shahid Beheshti University of Medical Sciences140
Not yet recruiting
Phase 3
Effectiveness and Safety of the drug Remogliflozin in diabetic patients with fat accumulation in liverCTRI/2020/02/023250Kshirsagar Shivani Prakash
Completed
Not Applicable
Efficacy and safety of Ipragliflozin in patients with type 2 diabetes who have inadequate glycemic control.Type 2 diabetesJPRN-UMIN000014306akakinen clinic100
Completed
Not Applicable
ong-term effects of ipragliflozin on diabetic nephropathy and blood pressure in patients with type 2 diabetesType 2 diabetes with diabetic nephropathyJPRN-UMIN000031157Ogawa Red Cross Hospital50